NCT06173284View on ClinicalTrials.gov

Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis

PHASE3RecruitingINTERVENTIONAL
Enrollment

510

Participants

Timeline

Start Date

January 22, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

May 31, 2026

Conditions
Dermatitis, Atopic
Interventions
DRUG

611

subcutaneous injection

DRUG

Matching placebo

subcutaneous injection

Trial Locations (4)

100044

NOT_YET_RECRUITING

Peking University People's Hospital, Beijing

310003

NOT_YET_RECRUITING

Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou

322000

RECRUITING

The Fourth Affiliated Hospital Zhejiang University School of Medicine, Jinhua

330200

NOT_YET_RECRUITING

Dermatology Hospital of Jiangxi Province, Nanchang

All Listed Sponsors
lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY